万孚生物收盘下跌1.03%，滚动市盈率21.81倍，总市值116.12亿元

Core Viewpoint - Wanfu Biological's stock closed at 24.12 yuan, down 1.03%, with a rolling PE ratio of 21.81 times and a total market value of 11.612 billion yuan, indicating a lower valuation compared to the industry average [1][2] Company Overview - Guangzhou Wanfu Biological Technology Co., Ltd. specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - The company has received numerous accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national-level "green factory" in January 2025 [1] Financial Performance - For Q1 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company's PE ratio (TTM) stands at 21.81, while the industry average is 55.46, indicating a significant valuation gap [2] Industry Comparison - In the medical device industry, Wanfu Biological ranks 46th in terms of PE ratio, with the industry median at 37.74 times [1][2] - Other companies in the industry have varying PE ratios, with the highest being 20.02 for Sanxin Medical and the lowest at 10.94 for Jiuan Medical [2]